Efficacy of Topical Metformin 30% Versus Minoxidil 5% in the Treatment of Alopecia Areata : Comparative Study

November 13, 2026 updated by: Arwa Ahmed Mohamed, Sohag University

This study aims to evaluate and compare the effectiveness and safety of topical metformin 30% and topical minoxidil 5% in patients with alopecia areata.

Alopecia areata is an autoimmune condition that causes non-scarring hair loss, usually presenting as round or oval patches on the scalp. Different topical treatments are used to stimulate hair regrowth, but their effectiveness varies.

In this comparative interventional study, eligible patients with alopecia areata will receive either topical metformin 30% or topical minoxidil 5%. Treatment response will be assessed clinically during follow-up using standardized assessment methods, including the Severity of Alopecia Tool (SALT) score, along with clinical and dermoscopic evaluation.

The study aims to determine whether topical metformin 30% is an effective treatment option compared with topical minoxidil 5% in patients with alopecia

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Sohag Governorate
      • Sohag, Sohag Governorate, Egypt
        • Recruiting
        • Sohag University Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients aged above 18 years to 40 years
  2. Both sexes.
  3. Patients with a clinical and dermoscopic diagnosis of localized alopecia areata.

Exclusion Criteria:

  1. Patients who received systemic or topical treatment for alopecia areata during the previous three months before the start of the study.
  2. Pregnant or lactating women.
  3. Patients with bleeding or coagulation disorders.
  4. Patients with autoimmune diseases.
  5. Patients with liver or renal diseases.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Topical Metformin 30%

Participants assigned to this arm will receive topical metformin 30% for the treatment of alopecia areata.

Topical metformin 30% preparation used for the treatment of alopecia areata.

Active Comparator: Topical Minoxidil 5%

Participants assigned to this arm will receive topical minoxidil 5% for the treatment of alopecia areata.

Topical minoxidil 5% preparation used for the treatment of alopecia areata.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in SALT Score from Baseline to Week 12
Time Frame: Baseline to Week 12 (12 weeks)

Assessment of the change in Severity of Alopecia Tool (SALT) score from baseline to week 12 to evaluate the therapeutic response to topical metformin 30% compared with topical minoxidil 5%. A decrease in SALT score indicates improvement in scalp hair loss.

Baseline to Week 12 (12 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 29, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

November 1, 2027

Study Registration Dates

First Submitted

November 13, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Soh-Med-26-10-4MS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.